Candidate tumour suppressor Fau regulates apoptosis in human cells: An essential role for Bcl-G  by Pickard, Mark R. et al.
Biochimica et Biophysica Acta 1812 (2011) 1146–1153
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbadisCandidate tumour suppressor Fau regulates apoptosis in human cells: An essential
role for Bcl-G
Mark R. Pickard ⁎, Mirna Mourtada-Maarabouni, Gwyn T. Williams ⁎⁎
Institute for Science and Technology in Medicine, Huxley Building, Keele University, Keele, ST5 5BG, UKAbbreviations: ALAS1, 5-Aminolevulinic acid synthas
ECL, enhanced chemo-luminescence; ERK, extracellular
Finkel-Biskis-Reilly murine sarcoma virus (FBR-Mu
expressed gene; FUBI, FAU ubiquitin-like protein; MCT,
ison test; MEK, MAPK/ERK kinase; RT-PCR, reverse tr
reaction; siRNA, small interfering RNA; z-VAD, benzylo
acid ﬂuoromethyl ketone
⁎ Corresponding author. Tel.: +44 1782 733678; fax:
⁎⁎ Corresponding author. Tel.: +44 1782 733032; fax:
E-mail addresses: m.r.pickard@biol.keele.ac.uk (M.R
g.t.williams@biol.keele.ac.uk (G.T. Williams).
0925-4439/$ – see front matter © 2011 Elsevier B.V. A
doi:10.1016/j.bbadis.2011.04.009a b s t r a c ta r t i c l e i n f oArticle history:
Received 31 January 2011
Received in revised form 8 April 2011
Accepted 21 April 2011
Available online 29 April 2011
Keywords:
Apoptosis
Bcl-2 family
BCL-L14
FUBI
Oncogenesis
Tumour suppressorFAU, which encodes a ubiquitin-like protein (termed FUBI) with ribosomal protein S30 as a carboxy-terminal
extension, has recently been identiﬁed as a pro-apoptotic regulatory gene. This activity may be mediated by
Bcl-G (a pro-apoptotic member of the Bcl-2 family) which can be covalently modiﬁed by FUBI. FAU gene
expression has been shown to be down-regulated in human breast, prostate and ovarian tumours, and this
down-regulation is strongly associated with poor prognosis in breast cancer. We demonstrate here that
ectopic FAU expression increases basal apoptosis in human T-cell lines and 293T/17 cells, whereas it has only a
transient stimulatory effect on ultraviolet-C (UVC)-induced apoptosis. Conversely, siRNA-mediated silencing
of FAU gene expression has no effect on basal apoptosis, but attenuates UV-induced apoptosis. Importantly,
prior knockdown of Bcl-G expression ablates the stimulation of basal apoptosis by FAU, consistent with an
essential downstream role for Bcl-G, itself a candidate tumour suppressor, in mediating the apoptosis
regulatory role of FAU. In 293T/17 cells, Bcl-G knockdown also attenuates UV-induced apoptosis, so that Bcl-G
may constitute a common factor in the pathways by which both FAU and UV-irradiation induce apoptosis.
UV irradiation increases Bcl-G mRNA levels, providing an explanation for the transient nature of the effect
of ectopic FAU expression on UV-induced apoptosis. Since failure of apoptosis is fundamental to the
development of many cancers, the pro-apoptotic activity of the Fau/Bcl-G pathway offers an attractive
explanation for the putative tumour suppressor role of FAU.e; ANOVA, analysis of variance;
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The retrovirus Finkel–Biskis–Reilly murine sarcoma virus (FBR-
MuSV) induces osteosarcomas in susceptible mice and contains the
transduced genes c-fos and fox [1]. Fox is an antisense sequence to the
cellular gene FAU (FBR-MuSV associated ubiquitously expressed
gene) and has been shown to increase the tumorigenicity of the
virus [1]. In addition, overexpression of FAU in Chinese hamster V79
cells has been shown to confer resistance to the carcinogen arsenite
[2]. Together, these observations indicate a tumour suppressor role for
the FAU gene. On the other hand, FAU has been reported to transform
human osteogenic sarcoma cells to anchorage-independence [3], sug-gesting that the FAU gene may additionally possess oncogenic activity
in certain circumstances.
FAU encodes a ubiquitin-like protein, termed FUBI, fused to
ribosomal protein S30 as a carboxy-terminal extension [4]. These
two products are thought to be cleaved post-translationally. FUBI has
37% amino acid sequence identity (57% sequence similarity) to
ubiquitin and retains the C-terminal G-G dipeptide motif that
participates in isopeptide bond formation between ubiquitin and
lysines of target proteins. It lacks, however, internal lysine residues
which serve as sites of polyubiquitin chain formation, indicating that
the biological function of FUBI is distinct from that of ubiquitin.
FUBI has been shown to interact with several proteins in murine
cells.When conjugated to a T-cell receptorα-like protein, it comprises
the β-subunit of murine monoclonal non-speciﬁc suppressor factor,
which exhibits immunomodulatory activity [5]. Interactions with
histone 2A (non-covalent modiﬁcation) [6] and Bcl-G (covalent
modiﬁcation) [7] also occur, and the FUBI/Bcl-G complex can associate
with ERKs and inhibit ERK activation by MEK1 [8]. Notably, Bcl-G is a
pro-apoptotic member of the Bcl-2 family [9], but the effect of FUBI-
mediated modiﬁcation of Bcl-G on apoptosis was not addressed in
these studies.
Using functional expression cloning approaches in murine cells,
our laboratory isolated two clones which confer resistance to
apoptotic cell death and which contain sequences antisense to FAU
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stimulate apoptosis in mouse W7.2c thymoma cells. Since failure of
apoptosis is fundamental to the development of many cancers [11,12]
regulation of apoptosis may serve as the functional basis of the
putative tumour suppressor role for FAU. It can be further postulated
that FUBI-mediated modiﬁcation of Bcl-G forms part of the molecular
mechanism by which FAU regulates apoptosis. Indeed, recent studies
in our laboratory have shown that FAU gene expression is down-
regulated in human breast, prostate and ovarian tumours [13–15] and
that siRNA-mediated silencing of FAU and BCL-L14 (which encodes
Bcl-G), either alone or in combination, attenuates apoptosis induction
in epithelial cell lines derived from such tissues [13,14]. Furthermore,
we have presented evidence which suggests that Fau and Bcl-G act in
the same apoptosis pathway in human breast and prostate cell lines
[13,14].
In the present study, we have tested the hypotheses that i. FAU
regulates apoptosis in human T-cell lines and HEK 293T/17 cells, and
ii. Bcl-G is essential for FAU action in the latter cell line.
2. Materials and methods
2.1. Materials
Culture media, supplements, molecular biology reagents and ﬁne
biochemicals were from Invitrogen (Paisley, UK) or Sigma-Aldrich
Company Ltd (Gillingham, UK). GeneJammer transfection reagent was
from Agilent Technologies UK Limited (Stockport UK) and RNAiFect
was from QIAGEN Ltd (Crawley, UK). siRNAs, Silencer siRNA labelling
kit, TaqMan Universal Master Mix and TaqMan Gene Expression Assays
were from Applied Biosystems (Warrington, UK). The CaspaTag
ﬂuorescein caspase activity kit was from Intergen (Oxford, UK).
Bradford Coomassie Plus Reagent was from Perbio Science UK Ltd
(Cramlington, UK). Ready gels, the GS-800 scanner and Quantity one
software were from Bio-Rad Laboratories (Hemel Hempstead, UK).
Immobilon-P membrane and the ReBlot Plus Kit were from Millipore
(Watford, UK) and ECL Western blotting detection reagent and
Hyperﬁlm-ECL were from GE Healthcare (Chalfont St. Giles, UK).
2.2. Cell lines
Human cell lines were employed, comprising the suspension cell
lines, Jurkat and CEM-C7 (both T-lymphoblastic leukaemia cells), and
the adherent cell line, 293T/17 (embryonic kidney-derived). Subclones
of Jurkat and CEM-C7 cells, previously generated in our laboratory
[16,17] and which exhibit uniform sensitivity to apoptosis induction
were used, whereas 293T/17 cells were obtained from ATCC-LGC
Promochem (Teddington, Middlesex, UK) and used directly. Cell lines
were routinely cultured in RPMI-1640 medium supplemented with
L-glutamine (2 mM), fetal bovine serum (10%) and gentamicin
(50 μg/ml).
2.3. Plasmid DNA transfection
pCMV-SPORT6-FAU (IMAGE clone: 5216042; accession BI908605;
GI: 16171620) was digested with EcoRI and XhoI and the insert was
directionally cloned into pcDNA3 to generate pcDNA3-Fau. The
orientation of the insert was veriﬁed by sequencing (Euroﬁns MWG
Operon, London, UK). GeneJammer transfection reagent was used for
transfection of 293T/17 cells, according to the manufacturer's in-
structions. Brieﬂy, transfections were conducted in 6-well (35 mm in
diameter) tissue culture dishes, and employed 2 μg plasmid (pcDNA3-
Fau or pcDNA3) and 10 μl transfection reagent per well. Jurkat and
CEM-C7 cells were transfected by electroporation using a gene pulser
with a capacitance extender unit (Bio-Rad Laboratories) in 4 mm gap
electroporation cuvettes. Early log phase cells were washed with –
and resuspended in – Opti-MEM I at 2×107 cells/ml. Cells (0.4 ml)were electroporated at room temperature with 40 μg plasmid at
1050 μF capacitance and either 238 V (CEM-C7 cells) or 292 V (Jurkat
cells). After 10 min, cells were added to 10 ml Iscove's Modiﬁed
Dulbecco's Medium (IMDM) supplementedwith L-glutamine (2 mM),
fetal bovine serum (20%) and gentamicin (50 μg/ml). Transfection
efﬁciency was assessed by carrying out parallel transfections with the
plasmid pEGFP (encodes a green ﬂuorescent protein) and the propor-
tion of cells exhibiting ﬂuorescence was determined by microscopy
24–48 h post-transfection. Transfection efﬁciencies were routinely
40–45% for 293T/17 and CEM-C7 cells and 45–50% for Jurkat cells.
2.4. RNA interference
Silencer predesigned siRNAs to FAU (codes 46005 and 10907;
herein termed Fau1 and Fau2, respectively) and BCL-L14 (codes
120721 and 120720; herein termed BclG1 and BclG2, respectively),
along with Silencer negative control #1 siRNA (code 4611) were
used here. RNAiFect was used for the transfection of 293T/17 cells,
according to the manufacturer's protocol. Transfections were con-
ducted in 6-well plates in culture medium and contained 30 nM
siRNA. Cells were transferred to T25 ﬂasks 24 h post-transfection and
maintained for 96 h before use. Suspension cells were transfected
with siRNA (30 nM ﬁnal concentration) by electroporation, using a
similar protocol to that described for plasmid transfection, except that
cells were allowed to incubate at room temperature for 20 min post-
electroporation before transfer to 10 ml of a 1:1 mix of complete
IMDM and routine culture medium. Cells were split 1:1 with routine
culture medium at 24 h post-transfection and maintained at 37 °C for
96 h before use.
To determine transfection efﬁciency, parallel transfections were
conducted with Cy3-labelled siRNA prepared using Silencer siRNA
labelling kit, according to the supplied protocol. The proportion of
cells exhibiting ﬂuorescence was determined by microscopy 24 h
post-transfection. Transfection efﬁciencies were routinely 50–55% for
CEM-C7 and Jurkat cells, and 80–85% for 293T/17 cells.
2.5. Induction of apoptosis
Suspension and trypsinised adherent cells were resuspended at
6×105 cells/ml culture medium, and irradiated with ultraviolet light
at 254 nm (UV). The doses administered were 20 J/m2 for Jurkat and
CEM-C7 cells and 40 J/m2 for 293T/17 cells and these doses were
veriﬁed using a UV (shortwave) intensity meter. Controls were mock-
irradiated. Immediately after exposure, cells were transferred to fresh
medium then plated (cell density of 2×104/cm2 for adherent cells or
3×105/ml for suspension cells). At the indicated times post-UV expo-
sure, cells were harvested for assessment of apoptosis; suspension
cells were studied directly, whereas 293T/17 cells were trypsinized
and adherent cells were combined with non-adherent cells prior to
assessment.
2.6. Assessment of apoptosis
Apoptosis was routinely monitored by assessment of nuclear
morphology. Cells were stained with acridine orange (25 μg/ml) and
observed by ﬂuorescence microscopy. Cells containing condensed or
fragmented chromatin were considered to be apoptotic.
In some experiments, apoptosis was additionally assessed by
measuring caspase activation using a commercial kit (CaspaTag
ﬂuorescein caspase activity kit), which contains a carboxyﬂuorescein
derivative of benzyloxycarbonyl valylalanylaspartic acid ﬂuoromethyl
ketone (z-VAD-fmk), according to the manufacturer's instruction;
cells were also stainedwith Hoechst 33342 to visualise cell nuclei. The
proportion of apoptotic cells was determined by ﬂuorescence micro-
scopy and direct counting.
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To assess short term cell viability, cell suspensions were stained
with 0.1% (w/v) nigrosin blue and counted using a Neubauer chamber
(light microscopy). Those cells which excluded the dye were con-
sidered to be viable.
2.8. Clonogenic growth assay
The colony forming ability of suspension cell lines was determined
by plating cells (ca. 10,000) in 3 ml complete IMDM further supple-
mentedwith 10% cell-conditionedmedium and 0.5% (w/v) Noble agar
in 6-well plates. The overlay comprised 1.5 ml complete IMDM
containing 10% cell-conditioned medium. Colonies were counted
after 3–4 weeks incubation. 293T/17 cells (ca. 200 cells) were directly
plated in 5 ml routine growth medium supplemented with 10% (v/v)
cell conditioned medium in 60 mm diameter culture dishes and
incubated for 10 days. Colonies were counted after staining with
crystal violet (0.5% (w/v) in methanol).
2.9. Real time RT-PCR
Total RNAwas isolated using TRIZOL reagent, digestedwith RNase-
free DNase, then reverse transcribed using random hexamer priming
and SuperScript II Reverse Transcriptase, according to the supplied
protocols. Real-time PCR was conducted using TaqMan Universal
Master Mix and TaqMan Gene Expression Assays (assay codes Hs
00609872_g1 for FAU, Hs 00373302_m1 for BCL2L14 and Hs
00167441_m1 for ALAS1), as recommended by the manufacturer,
and was run on an ABI Prism Sequence Detection Systemmodel 7000.
A standard curve, comprising cDNA prepared from the 22Rv1 human
prostate cell line, was included with each assay run to allow relative
quantitation. Assays usually contained 0.1–30 ng standard or 5 ng
sample cDNA in a ﬁnal volume of 25 μl. For quantitation of Bcl-G,
which is a low abundance mRNA, sample and standard input were
500 ng and 0.6–60 ng cDNA, respectively. For each assay, a standard
curve of threshold cycle (CT) value versus log input standard cDNA
was constructed by linear regression, and the equation of the line was
used to calculate input amounts of samples from their respective
CT values. Bcl-G sample values were corrected for increased sample
input, and all data were expressed relative to the endogenous control
gene, ALAS1.
2.10. Immunoblotting
Cells were washed twice with PBS and resuspended in ice-cold
RIPA buffer containing 1% (v/v) Calbiochem protease inhibitor
cocktail set III and 0.2 mM iodoacetamide. After 30 min at 4 °C,
samples were centrifuged (10,000 g; 10 min; 4 °C) and the protein
content of the supernatant was assayed using Bradford Coomassie
Plus Reagent. Samples (15 μg protein) were denatured with Laemmli
buffer by boiling (10 min), then centrifuged (10,000 g; 10 min; 4 °C).
Supernatants were electrophoresed (12% Tris–HCl Ready gels), then
electrotransferred in Towbin buffer to Immobilon-P membrane.
Immunodetection was by a standard protocol supplied with the ECL
Western blotting detection reagent. For Bcl-G, primary antibody (code
PA1-4209; Afﬁnity BioReagents, Golden, CO) was used at 1:2000
dilution, and secondary antibody (goat anti-rabbit IgG; peroxidase-
conjugate; code A0545, Sigma-Aldrich Company Ltd) was used at
1:10000 dilution. Blots were stripped (ReBlot Plus Kit) and reprobed
for β-actin, using primary antibody (code A5441; Sigma-Aldrich
Company Ltd) at a dilution of 1:10000 and secondary antibody (goat
anti-mouse immunoglobulins, peroxidase-conjugate, code P0447;
Dako, Ely, UK) at a dilution of 1:5000. Blots were then exposed to
Hyperﬁlm-ECL (preﬂashed to 0.05 optical density units above
background). Images were captured and densitometrically analysedusing a GS-800 scanner and Quantity one software (both from Bio-Rad
Laboratories).
2.11. Statistical analysis
Data were analysed by Student's t-test (unpaired) or, for com-
parison of more than two groups, by one-way analysis of variance.
Post-hoc analysis for the latter was by Bonferroni's multiple com-
parison test (MCT) or, when comparing data to a single control group,
by Dunnett's MCT.
3. Results
3.1. Ectopic expression of FAU
Transient transfection of CEM-C7, Jurkat and 293T/17 cell lines
with pcDNA3-Fau markedly increased FAU mRNA levels: FAU/ALAS1
ratios for pcDNA3-Fau versus pcDNA3 transfectants were: 5.41±0.83
versus 1.79±0.03 for CEM-C7, 5.65±1.38 versus 0.93±0.31 for
Jurkat, and 16.05±1.93 versus 0.49±0.27 for 293T/17 (all Pb0.01,
n≥3; Student's t-test). In all cell lines, ectopic FAU expression was
associated with increased apoptosis and decreased short-term cell
viability in the absence of UV-irradiation (Fig. 1). In contrast, there
was no consistent effect on UV-induced apoptosis, at least at the time
points studied in this experiment (Fig. 1). However, in a further study,
assay of pan-caspase activity in CEM-C7 cells revealed that ectopic
FAU expression was associated with increases in both basal and UV-
induced apoptosis at 4.5 h post-UV irradiation (the proportion of
ﬂuorescent cells for pcDNA3-Fau versus pcDNA3 transfectants were:
56.6±2.4 versus 28.4±1.8% for mock-irradiated cells and 60.2±4.6
versus 37.2±4.5% for UV-irradiated cells; both Pb0.01, n=3; one-
way ANOVA and Bonferroni's MCT), whereas, at 24 h post-UV irra-
diation, basal apoptosis only was increased (data not shown).
In separate experiments, the colony-forming ability of CEM-C7,
Jurkat and 293T/17 cells transiently transfectedwith FAUwas found to
be reduced when compared with cells transfected with vector alone
(Fig. 2), conﬁrming the signiﬁcant pro-apoptotic role of FAU in these
cell lines, even when FAU expression was transient. Furthermore,
there was no signiﬁcant effect of FAU on clonogenic survival of UV-
irradiated cells (data not shown) in keeping with our observations on
short-term cell viability (Fig. 1).
3.2. Silencing of FAU expression
Two different siRNAs (termed Fau1 and Fau2 siRNAs) were
employed to examine the effects of FAU gene silencing on apoptosis.
FAU/ALAS1 transcript ratios for cells transfected with Fau1 and Fau2
versus negative control siRNAs were: 1.14±0.11 and 1.08±0.16 vs
2.17±0.17 for CEM-C7 cells; 0.70±0.05 and 0.64±0.07 vs 1.25±
0.02 for Jurkat cells, and 0.23±0.01 and 0.26±0.01 vs 0.51±0.08 for
293T/17 cells (all Pb0.01, n≥3; one-way ANOVA and Dunnett's MCT).
Thus, FAU gene expression was reduced by approximately one half
with each siRNA. In all cell lines, this had negligible effects on apo-
ptosis and cell viability in the absence of an apoptotic stimulus, but
markedly attenuated UV-induced apoptosis and loss of cell viability
(Fig. 3).
3.3. Mediation of FAU pro-apoptotic activity by Bcl-G
Fau, or, more speciﬁcally, the FUBI moiety, has been shown to
covalently modify a pro-apoptotic member of the Bcl-2 family, Bcl-G
[7]. It is possible therefore, that Bcl-G is involved in the pro-apoptotic
action of Fau.
To address this postulate, we ﬁrstly investigated the effect of
siRNA-mediated silencing of Bcl-G on apoptosis in 293T/17 cells. Two
different Bcl-G siRNAs were studied, both of which reduced Bcl-G
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Fig. 1. Transient over-expression of Fau in T-cell lines and 293T/17 cells inﬂuences apoptosis and cell viability. Cells were transfected with a pcDNA3-Fau construct or pcDNA3 alone
and, after 24 h, either exposed to UV light or mock-irradiated. The proportion of apoptotic cells was determined by acridine orange staining after a further 24 h (T-cell lines) or 48 h
(293T/17 cells), whereas short-term cell viability was determined by dye exclusion at 48 h post-UV irradiation. Panels A–H: example images of acridine orange-stained Jurkat (A–D)
and 293T/17 (panels E–H) cells; vector/treatment conditions are: pcDNA3/mock-irradiated (panels A and E); pcDNA3/UV-irradiated (panels B and F); pcDNA3-Fau/mock-irradiated
(panels C and G); and pcDNA3-Fau/UV-irradiated (panels D and H); cells showing condensed and/or fragmented chromatin, characteristic of apoptosis, are indicated by arrows;
scale bar in panel A also applies to panels B–H. Panels I–K: bar charts showing proportion of apoptotic cells in transfected CEM-C7 (panel I), Jurkat (panel J) and 293T/17 (panel K)
cultures; UV-irradiated cells are closed bars and mock-irradiated controls are open bars. Panels L–N: bar charts showing proportion of apoptotic cells in transfected CEM-C7 (panel
L), Jurkat (panel M) and 293T/17 (panel N) cultures; UV-irradiated cells are closed bars and mock-irradiated controls are open bars Data(panels I–N) are mean±SEM; *Pb0.05,
**Pb0.01, ***Pb0.001, pcDNA3-Fau versus pcDNA3 (mock-irradiated) and +Pb0.05 pcDNA3-Fau versus pcDNA3 (UV-irradiated) (one-way ANOVA and Bonferroni's MCT); n=6 (T-
cell lines) or n=4 (293T/17 cells).
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silencing of Bcl-G expression was found to attenuate UV-induced
increases in pan-caspase activity (Fig. 4C) and cell death (Fig. 4D),
similar to the effects of silencing of FAU expression (Fig. 3).
Next, the effect of Bcl-G knockdown on FAU-mediated stimulation
of the basal apoptotic rate was examined. For this experiment,
293T/17 cells were ﬁrst transfected with one of the two different
siRNAs to the BCL-L14 gene or negative control siRNA, then (after
4 days) transfected with either the pcDNA3-Fau construct or pcDNA3
alone. At 24 h after the second transfection, Bcl-G mRNA levels were
reduced (Pb0.01, n=4; one-way ANOVA and Dunnett's MCT) in cellstransfected with BclG1 and BclG2 siRNAs when compared with
negative control siRNA, irrespective of whether cells had received
pcDNA3-Fau or pcDNA3 alone in the second round of transfection
(pooled Bcl-G/ALAS1 ratios for NC, BclG1 and BclG2 siRNAs were:
0.0137±0.0015, 0.0074±0.0010 and 0.0071±0.0009, respectively).
Similarly, FAUmRNA levels were increased (Pb0.001, n=4; Student's
t-test) in cells transfected with the pcDNA3-Fau construct when
compared with those transfected with pcDNA3 alone, irrespective of
whether cells had received negative control, BclG1 or BclG2 siRNA in
the ﬁrst round of transfection (pooled FAU/ALAS1 ratios for pcDNA3
and pcDNA3-Fau transfectants were: 0.34±0.04 and 14.59±2.15,
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Fig. 2. Transient over-expression of Fau reduces the clonogenic activity of T-cell lines
and 293T/17 cells. CEM-C7 (panel A), Jurkat (panel B) and 293T/17 (panel C) cells were
transfected with a pcDNA3-Fau construct or pcDNA3 alone and, after 24 h, aliquots
were plated in soft-agar (T-cell lines) or direct onto tissue culture plastic (293T/17
cells). Colonies of T-cell lines were counted by direct observation after 3–4 weeks
incubation, whereas colonies of 293T/17 cells were counted following crystal violet
staining after 1–2 weeks incubation. Data are mean±SEM; *Pb0.01, **Pb0.005,
pcDNA3-Fau versus pcDNA3 (Student's t-test); n=10.
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increased apoptosis and reduced both short-term viability and
clonogenic survival in cells which had been previously transfected
with negative control siRNA (Fig. 5 & data not shown), as expected.
However, in cells which had been pre-treated with siRNAs to BCL-L14,
this pro-apoptotic activity of FAUwas either markedly reduced (in the
case of BclG1 siRNA) or abolished (in the case of BclG2 siRNA) (Fig. 5).
Similarly, FAU was without any signiﬁcant effect on short-term
viability (data not shown) and clonogenic survival (Fig. 5) in cells pre-
treated with siRNAs to BCL2-L14. Thus, these ﬁndings support an
essential role for Bcl-G in mediating the stimulation of basal apoptosis
by Fau.
3.4. Effect of ectopic FAU expression and siRNA-mediated silencing of
FAU on Bcl-G protein levels
Ubiquitin (and several ubiquitin-like proteins) often regulate the
proteasomal degradation of target molecules [18–21]. Despite
showing high homology with ubiquitin, FAU-encoded FUBI lacks
internal lysine residues usually associated with polyubiquitin chain
formation, thus mechanism(s) involving FAU-mediatedmodulation of
Bcl-G protein levels appear unlikely. To examine this postulate, steady
state levels of Bcl-G protein (speciﬁcally the long isoform of Bcl-G)
were determined in T-cell lines and 293T/17 cells after modulation of
FAU gene expression. Indeed, neither ectopic FAU expression norsiRNA-mediated silencing of FAU were associated with changes in
Bcl-G protein levels in any of the three cell lines (Fig. 6).
3.5. Effect of UV-irradiation on FAU and BCL2-L14 gene expression in
HEK 293T/17 cells
One possible explanation for the lack of any sustained effect of
ectopic FAU gene expression on UV-induced apoptosis, as demon-
strated earlier (e.g. see Fig. 1), is that both Fau- and UV-induced
apoptosis may in part be mediated through common factor(s). Having
shown that Bcl-G is necessary for Fau-mediated stimulation of the
basal apoptotic rate, and given that BCL2-L14 is a putative p53-
responsive gene [22], the effect of UV irradiation on Bcl-G (and Fau)
mRNA levels in 293T/17 cells (which express a functional p53) was
examined. Whilst UV-irradiation resulted in a robust induction in Bcl-
G gene expression (Fig. 7A), it did not affect steady state Fau mRNA
levels (Fig. 7B).
4. Discussion
We show here that ectopic FAU expression stimulates the basal
apoptotic rate in human T-cell lines and in 293T/17 cells. Conversely,
siRNA-mediated down-regulation of endogenous FAU expression
attenuates UV-induced apoptosis in all three cell lines. These ﬁndings
are in broad agreement with earlier studies in murine cells [10] and in
human breast, prostate and ovarian cell lines [13–15], demonstrating
that FAU regulates apoptosis in multiple mammalian cell types.
FAU encodes a ubiquitin-like protein, termed FUBI, with ribosomal
protein S30 as a carboxy-terminal extension. In mouse cells, FUBI
covalently modiﬁes a pro-apoptotic member of the Bcl-2 family, Bcl-G
[7]. This prompted us to investigate whether Bcl-G was required for
the apoptosis-promoting activity of FAU in human cells. Similar to
the effects of Fau knockdown, siRNA-mediated silencing of Bcl-G
expression attenuated UV-induced apoptosis in 293T/17 cells,
consistent with ﬁndings in breast and prostate cell lines [13,14].
Crucially, in the present study, prior knockdown of BCL-L14 (Bcl-G)
gene expression was found to abolish the increase in basal apoptotic
rate consequent upon ectopic FAU expression, despite an increase in
apoptosis produced by the Bcl-G siRNAs alone (Fig. 5). This ﬁnding
supports the hypothesis that Bcl-G plays an essential down-stream
role in mediating the pro-apoptotic activity of Fau. Indeed, consistent
conclusions have been drawn from studies on the effects of FAU and
BCL2-L14 down-regulation in breast and prostate cell lines: Although
down-regulation of each gene alone attenuates UV-induced apopto-
sis, no additional effect is produced when the two genes are down-
regulated together [13,14].
While ectopic FAU expression resulted in a sustained increase in
the basal apoptotic rate in all cell lines, effects on UV-induced
apoptosis appeared more transient, being limited to the ﬁrst few
hours after UV irradiation. Thus in CEM-C7 cells, FAU enhanced UV-
induction of caspase activity at 4.5 h post-irradiation but this effect
had disappeared by 24 h. One explanation for this ﬁnding is that the
mechanisms by which FAU and UV-irradiation induce apoptosis
involve a common factor; several lines of evidence from the present
study suggest that this factor is Bcl-G. Firstly, Bcl-G is essential for
stimulation of the basal apoptotic rate by Fau; secondly, siRNA-
mediated silencing of Bcl-G expression attenuates UV-induced
apoptosis, and thirdly, UV irradiation induces BCL2-L14 (but not
FAU) gene expression; consistent with the identiﬁcation of BCL2-L14
as a putative p53-responsive gene [22]. Thus, when cellular FAU gene
expression is enhanced, basal apoptosis is increased by a mechanism
centring on Bcl-G. However, when the same cell is subsequently
exposed to high levels of UV irradiation, Bcl-G expression increases, so
that the pro-apoptotic effect of Bcl-G per se are likely to predominate
at later time points.
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Fig. 4. siRNA-mediated knockdown of Bcl-G attenuates induction of apoptosis by UV irradiation in 293T/17 cells. Cells were transfected with siRNA to BCL2L14 (BclG1or BclG2 siRNA)
or negative control (NC) siRNA. After 96 h, samples were taken for assessment of Bcl-G mRNA and protein levels, and cells were then either exposed to UV (closed bars) or mock
irradiated (open bars). Cells were assessed for apoptosis (C; CaspaTag assay) and cell viability (D; vital dye staining) after a further 48 h. A) Bcl-G RNA levels expressed relative to the
house-keeping gene ALAS1; *Pb0.01 versus NC siRNA (one-way ANOVA and Dunnett's MCT); n=4. B) Bcl-G protein levels expressed relative to β-actin; *Pb0.05 versus NC siRNA
(one-way ANOVA and Dunnett's MCT); n=4. C) Proportion of apoptotic cells in UV-treated (closed bars) and mock-irradiated cells (open bars); *Pb0.001 versus mock-irradiated
control (one-way ANOVA and Bonferroni's MCT); n=4. D) Cell viability in UV-treated (closed bars) and mock-irradiated (open bars) cultures; *Pb0.05, versus mock-irradiated
control (one-way ANOVA and Bonferroni's MCT); n=4.
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Fig. 3. siRNA-mediated knockdown of Fau expression in CEM-C7, Jurkat and 293T/17 attenuates UV-induced apoptosis. CEM-C7 (panels A and D), Jurkat (panels B and E) and
293T/17 (panels C and F) cells were transfected with two different siRNAs to Fau (Fau1 and Fau2) or negative control (NC) siRNA and cultured for 96 h. Cells were either exposed to
UV light (closed bars) or mock-irradiated (open bars) and, after 48 h, the proportion of apoptotic cells was determined by acridine orange staining (panels A–C) and short-term cell
viability was determined by dye exclusion (panels D–F). Data are mean±SEM; *Pb0.05, **Pb0.01, ***Pb0.001, Fau1 or Fau2 versus NC siRNA (UV-irradiated) (one-way ANOVA and
Bonferroni's MCT); n=8 (CEM-C7 cells), n=6 (Jurkat cells) or n=3 (293T/17 cells).
1151M.R. Pickard et al. / Biochimica et Biophysica Acta 1812 (2011) 1146–1153
A0
10
20
30
40
**
*
%
 F
lu
or
es
ce
nt
B
0
5000
10000
15000
20000
25000
**
Co
lo
ni
es
 p
er
 1
0^
5 
ce
lls
BclG1NC BclG2
Fig. 5. siRNA-mediated knockdown of Bcl-G attenuates induction of apoptosis by Fau in
293T/17 cells. Cells were transfected with two different siRNAs to BCL2L14 (BclG1 and
BclG2) or negative control (NC) siRNA. After 96 h, cells were transfected with a
pcDNA3-Fau construct (closed bars) or pcDNA3 alone (open bars). After a further 24 h,
cells were re-plated for assessment of apoptosis (by CaspaTag at 48 h post-plating;
panel A) and colony formation (by crystal violet staining after 10 days; panel B). Data
are mean±SEM; *Pb0.01, **Pb0.001, pcDNA3-Fau versus pcDNA3 (one-way ANOVA
and Bonferroni's MCT); n=4. C
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Fig. 6. Effect of ectopic FAU expression and siRNA-mediated silencing of FAU gene
expression on Bcl-G protein levels in CEM-C7 (panel A), Jurkat (panel B) and 293T/17
(panel C) cells. Cells were transfected with pcDNA3, pcDNA3-Fau, a negative control
(NC) siRNA or one of two different siRNAs to FAU (Fau1 and Fau2). Cells were
harvested for Western blot preparation at either 48 h (pcDNA3 and pcDNA3-Fau
transfectants) or 96 h (siRNA-transfected cells) post-transfection. Blots were
immunodetected with an antibody to Bcl-G, stripped, then with an antibody to
β-actin; resulting images were analysed densitometrically. Data are expressed as
Bcl-G:β-actin ratio; n≥3 cultures.
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[19–21], and, in addition, it is increasingly recognised that a range of
ubiquitin-like proteins, in particular SUMO-1, DAP-1 and Fat-10, have
roles in apoptosis control [23–26]. Findings from present and previous
studies [7,13–15] raise the possibility that FAU-derived FUBI also falls
into the latter category.
Ubiquitin controls the levels of many key apoptosis regulatory
molecules (including p53, the inhibitor of nuclear factor ΚB, c-FLIP,
inhibitor of apoptosis proteins (IAPs) and Bcl-2 family members) via
the formation of lysine-48 polyubiquitin chains, facilitating their
proteasomal degradation [19–21]. A similar mechanism of action is
unlikely for FUBI, since lysine-48 is not conserved in this ubiquitin-
like protein. Indeed, with the exception of certain members of the
SUMO family, ubiquitin-like proteins are not thought to form chains
on target molecules [18]. Consistent with this, cellular Bcl-G protein
levels were unaffected by up- or down-regulation of FAU gene
expression in the present study. However, an increasing body of
evidence indicates that modiﬁcation of proteins with monomers of
ubiquitin or ubiquitin-like proteins, rather than inducing degradation,
markedly inﬂuences their activity, intracellular localisation or inter-
molecular interactions [18–21,27]. In this regard, the FUBI/Bcl-G
complex has been shown to associate with ERKs and to inhibit ERK
activation by MEK1 in murine cells [8]. Nevertheless, the molecular
mechanisms by which FAU regulates apoptosis remain to be
elucidated; possibilities include FUBI-mediated targeting of Bcl-G to
the mitochondrion, or modulation of the interaction of Bcl-G with
other constituents of the cellular apoptotic machinery, for example.
Although down-regulation of Bcl-G clearly inhibits apoptosis
induced both by UV irradiation and by Fau (Figs. 4 and 5), basal apo-
ptosis rates are higher under these conditions. This is a reproducible
and speciﬁc effect of two independent Bcl-G siRNAs in 293T/17 cells,
but it has not been observed in other cell lines [13,14]. This indicates
that in certain cell lines, such as 293T/17, Bcl-G can have anti-
apoptotic effects, in addition to the pro-apoptotic effects generally
associated with BH3-only members of the Bcl-2 family. Whilst suchactivity has not previously been reported for Bcl-G, anti-apoptotic
activity has also previously been reported for the BH3-only protein N-
Bak [28].
In summary, present and previous ﬁndings are consistent with
a pro-apoptotic regulatory role for FAU, mediated via Bcl-G. This
activity is likely to be of clinical importance since FAU expression is
down-regulated in several tumours, including those that affect the
prostate, the ovaries and the breast (where down-regulation of Fau is
signiﬁcantly associated with poor prognosis), and probably consti-
tutes the functional basis of the putative tumour suppressor gene
function of FAU. More detailed understanding of the FAU/Bcl-G path-
way is warranted, since this may facilitate the design of novel cancer
chemotherapies.
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Fig. 7. Effect of UV-irradiation on BCL2L14 (panel A) and FAU (panel B) gene expression
in 293T/17 cells. Cells were irradiated with a UV-dose of 40 J/m2, then after 24 h, RNA
was extracted and cDNA was prepared. This was subjected to real-time PCR analysis for
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